Core Viewpoint - 联康生物科技集团 has entered into a strategic cooperation agreement with 科兴制药 for the exclusive commercialization of its innovative osteoporosis treatment drug, 博固泰, in six countries [1] Group 1: Company Overview - 联康生物科技集团's subsidiary, 北京博康健基因科技有限公司, will collaborate with 科兴制药 to expand the market for 博固泰 in Saudi Arabia, Egypt, Morocco, Colombia, Argentina, and Mexico [1] - 博固泰 is recognized as China's first approved pre-filled teriparatide injection, designed to enhance patient comfort and adherence through a fine needle and precise delivery system [1] Group 2: Product Details - 博固泰 is a next-generation osteoporosis treatment that promotes bone formation and increases bone density, addressing significant unmet medical needs for postmenopausal women at high risk of fractures [1]